On Oct, 7, 2016, IPCI "received tentative approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths."
On Oct, 13, 2016, IPCI's 3Q came out and it was a miss and the stock slid, only to come back into the $3 range for a few days near the time of the NDA app. for Rexista was submitted (Nov 25). Let's hope for the $3 range and more next time. I doubt it will last once the shorts get back into business.